Terbutaline Concentrations in Blood and Urine

Blood and Urinary Concentrations of Terbutaline in Asthmatics and Elite Athletes With Asthma: Comparison Between Inhalation vs. Oral Administration.

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00914797

Enrollment

Registered

2009-06-05

Start date

2009-07-31

Completion date

2010-03-31

Last updated

2009-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Doping, Beta agonist, Terbutaline, Pharmacokinetics

Brief summary

The purpose of this study is to assess the blood and urine concentrations of terbutaline and to evaluate the difference between inhaled and oral terbutaline in order to distinguish treatment with terbutaline from doping with terbutaline in a doping control.

Detailed description

To investigate the serum and urine concentrations of terbutaline and evaluate the difference between inhaled terbutaline (2 mg) and oral terbutaline (10 mg) in order to distinguish doping with terbutaline from anti-asthmatic treatment with terbutaline. To investigate the above mentioned in three groups: healthy men, male asthmatic subjects and male elite athletes with asthma.

Interventions

DRUGinhaled and oral terbutaline

Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage. Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076. Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954.

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Physician-diagnosed asthma with positive reversibility or challenge test. * Informed consent. * Age between 18 - 45 years. * Sex: male. * Asthma classified as mild to moderate according to GINA guidelines. * Used beta-2-agonist in minimum 12 months.

Exclusion criteria

* Smokers or ex-smokers with a smoking history of 10 pack years or more. * Respiratory tract infections within the last 2 weeks prior to visit 1 and 2. * Subjects with other chronic diseases than asthma and allergy. * Allergy towards the study medicine. * Use of beta-2-agonist 6 days prior to study day.

Design outcomes

Primary

Measure	Time frame
Terbutaline concentrations in serum and urine	baseline, 4, 8, and 12 hours after medicine administration

Countries

Denmark

Contacts

Primary ContactJimmi Elers½, MD

jele0004@bbh.regionh.dk+45 35313208

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026